Cas:146351-72-6 methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate manufacturer & supplier

Chemical Name:methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate

CAS.NO:146351-72-6

Synonyms:methyl t-butyldimethylsilyloxyacetate

Molecular Formula:C₉H₂₀O₃Si

Molecular Weight:204.33900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.53000

Exact Mass:204.11800

LogP:2.18120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like methyl t-butyldimethylsilyloxyacetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl t-butyldimethylsilyloxyacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl t-butyldimethylsilyloxyacetate Use and application,methyl t-butyldimethylsilyloxyacetate technical grade,usp/ep/jp grade.

Related News: Beijing will strengthen its monitoring of overseas drug market and collect global prices for imported medicines, Friday��s guideline said. methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate manufacturer FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate supplier The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate vendor FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. methyl 2-[tert-butyl(dimethyl)silyl]oxyacetate factory FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.